Abionyx Pharma soars after approval for COVID-19 treatment

Abionyx Pharma SA

04/01/2022 08:31

** Shares of Abionyx Pharma  ABNX.PA  jump more than 27%
after the French biopharmaceutical group received compassionate
access authorization by French Drug Safety Agency to use the HDL
biomolecule CER-001 in the treatment of patients with COVID-19
 urn:newsml:reuters.com:*:nFWN2TJ02J
    ** Boosting HDL levels by injecting the molecule could be
one way to help patients recover from COVID-19, a condition for
which there is no suitable treatment available at present,
Midcap Partners says 
    ** The company also has the means to finance its
developments with 4.2 million euros ($4.74 million) raised in
December 2021, the brokerage adds
    ** The broker notes developments could accelerate with the
availability of new batches of the CER-001 molecule
    ** Abionyx shares are on track for their best day since Nov.
29, when they closed 29.0% higher

($1 = 0.8860 euros)

 (Reporting by Kate Entringer)
 ((kate.entringer@thomsonreuters.com))